CLOVIQUE Drug Patent Profile
✉ Email this page to a colleague
When do Clovique patents expire, and what generic alternatives are available?
Clovique is a drug marketed by Chartwell Rx and is included in one NDA.
The generic ingredient in CLOVIQUE is trientine hydrochloride. There are ten drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the trientine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Clovique
A generic version of CLOVIQUE was approved as trientine hydrochloride by WATSON LABS TEVA on February 7th, 2018.
Summary for CLOVIQUE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CLOVIQUE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for CLOVIQUE
US Patents and Regulatory Information for CLOVIQUE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chartwell Rx | CLOVIQUE | trientine hydrochloride | CAPSULE;ORAL | 209731-001 | Oct 21, 2019 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |